Search

Your search keyword '"Ou, Xichao"' showing total 24 results
Start Over Author "Ou, Xichao" Publication Year Range Last 3 years
24 results on '"Ou, Xichao"'

5. Transmission characteristics in Tuberculosis by WGS: nationwide cross-sectional surveillance in China

Author

Liu, Dongxin, primary, Huang, Fei, additional, Li, Yaru, additional, Mao, Lingfeng, additional, He, Wencong, additional, Wu, Sihao, additional, Xia, Hui, additional, He, Ping, additional, Zheng, Huiwen, additional, Zhou, Yang, additional, Zhao, Bing, additional, Ou, Xichao, additional, Song, Yuanyuan, additional, Song, Zexuan, additional, Mei, Li, additional, Liu, Li, additional, Zhang, Guoliang, additional, Wei, Qiang, additional, and Zhao, Yanlin, additional

Published
2024
Full Text
View/download PDF

6. Impact of MSMEG5257 Deletion on Mycolicibacterium smegmatis Growth

Author

He, Ping, primary, Zhao, Bing, additional, He, Wencong, additional, Song, Zexuan, additional, Pei, Shaojun, additional, Liu, Dongxin, additional, Xia, Hui, additional, Wang, Shengfen, additional, Ou, Xichao, additional, Zheng, Yang, additional, Zhou, Yang, additional, Song, Yuanyuan, additional, Wang, Yiting, additional, Cao, Xiaolong, additional, Xing, Ruida, additional, and Zhao, Yanlin, additional

Published
2024
Full Text
View/download PDF

7. Prevalence and genetic basis of Mycobacterium tuberculosis resistance to pretomanid in China.

Author

Zhao, Bing, Zheng, Huiwen, Timm, Juliano, Song, Zexuan, Pei, Shaojun, Xing, Ruida, Guo, Yajie, Ma, Ling, Li, Feina, Li, Qing, Li, Yan, Huang, Lin, Teng, Chong, Wang, Ni, Gupta, Aastha, Juneja, Sandeep, Huang, Fei, Zhao, Yanlin, and Ou, Xichao

Subjects
MYCOBACTERIUM tuberculosis, DRUG resistance, TUBERCULOSIS, GENOTYPES
Abstract

Background: Pretomanid is a key component of new regimens for the treatment of drug-resistant tuberculosis (TB) which are being rolled out globally. However, there is limited information on the prevalence of pre-existing resistance to the drug. Methods: To investigate pretomanid resistance rates in China and its underlying genetic basis, as well as to generate additional minimum inhibitory concentration (MIC) data for epidemiological cutoff (ECOFF)/breakpoint setting, we performed MIC determinations in the Mycobacterial Growth Indicator Tube™ (MGIT) system, followed by WGS analysis, on 475 Mycobacterium tuberculosis (MTB) isolated from Chinese TB patients between 2013 and 2020. Results: We observed a pretomanid MIC distribution with a 99% ECOFF equal to 0.5 mg/L. Of the 15 isolates with MIC values > 0.5 mg/L, one (MIC = 1 mg/L) was identified as MTB lineage 1 (L1), a genotype previously reported to be intrinsically less susceptible to pretomanid, two were borderline resistant (MIC = 2–4 mg/L) and the remaining 12 isolates were highly resistant (MIC ≥ 16 mg/L) to the drug. Five resistant isolates did not harbor mutations in the known pretomanid resistant genes. Conclusions: Our results further support a breakpoint of 0.5 mg/L for a non-L1 MTB population, which is characteristic of China. Further, our data point to an unexpected high (14/475, 3%) pre-existing pretomanid resistance rate in the country, as well as to the existence of yet-to-be-discovered pretomanid resistance genes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Association of lineage 4.2.2 of Mycobacterium tuberculosis with the 63-bp deletion variant of the mpt64 gene

Author

Song, Zexuan, primary, He, Wencong, additional, Pei, Shaojun, additional, Zhao, Bing, additional, Cao, Xiaolong, additional, Wang, Yiting, additional, He, Ping, additional, Liu, Dongxin, additional, Ma, Aijing, additional, Ou, Xichao, additional, Xia, Hui, additional, Wang, Shengfen, additional, Liu, Chunfa, additional, and Zhao, Yanlin, additional

Published
2023
Full Text
View/download PDF

10. Insight into the drug-resistant characteristics and genetic diversity of multidrug-resistant Mycobacterium tuberculosis in China

Author

Song, Zexuan, primary, Liu, Chunfa, additional, He, Wencong, additional, Pei, Shaojun, additional, Liu, Dongxin, additional, Cao, Xiaolong, additional, Wang, Yiting, additional, He, Ping, additional, Zhao, Bing, additional, Ou, Xichao, additional, Xia, Hui, additional, Wang, Shengfen, additional, and Zhao, Yanlin, additional

Published
2023
Full Text
View/download PDF

11. Proficiency testing for drug susceptibility testing of Mycobacterium tuberculosiscomplex using commercial broth microdilution plate in China in 2021

Author

Xia, Hui, Song, Yuanyuan, Zheng, Yang, Zhou, Yang, Ou, Xichao, Wang, Shengfen, Zhao, Bing, and Zhao, Yanlin

Abstract

•The drug layout and operation procedures varied between studied BMD plates.•Performance differed between types of plate and drugs.•Proficiency of laboratory staff may affect the performance.

Published
2024
Full Text
View/download PDF

13. Endogenous relapse and exogenous reinfection in recurrent pulmonary tuberculosis: A retrospective study revealed by whole genome sequencing

Author

He, Wencong, primary, Tan, Yunhong, additional, Song, Zexuan, additional, Liu, Binbin, additional, Wang, Yiting, additional, He, Ping, additional, Xia, Hui, additional, Huang, Fei, additional, Liu, Chunfa, additional, Zheng, Huiwen, additional, Pei, Shaojun, additional, Liu, Dongxin, additional, Ma, Aijing, additional, Cao, Xiaolong, additional, Zhao, Bing, additional, Ou, Xichao, additional, Wang, Shengfen, additional, and Zhao, Yanlin, additional

Published
2023
Full Text
View/download PDF

18. Whole-genome sequencing for surveillance of tuberculosis drug resistance and determination of resistance level in China

Author

Liu, Dongxin, primary, Huang, Fei, additional, Zhang, Guoliang, additional, He, Wencong, additional, Ou, Xichao, additional, He, Ping, additional, Zhao, Bing, additional, Zhu, Baoli, additional, Liu, Fei, additional, Li, Zhiyuan, additional, Liu, Chunfa, additional, Xia, Hui, additional, Wang, Shengfen, additional, Zhou, Yang, additional, Walker, Timothy M., additional, Liu, Lei, additional, Crook, Derrick W., additional, and Zhao, Yanlin, additional

Published
2022
Full Text
View/download PDF

21. Drug-Resistant Characteristics, Genetic Diversity, and Transmission Dynamics of Rifampicin-Resistant Mycobacterium tuberculosis in Hunan, China, Revealed by Whole-Genome Sequencing

Author

He, Wencong, primary, Tan, Yunhong, additional, Liu, Chunfa, additional, Wang, Yiting, additional, He, Ping, additional, Song, Zexuan, additional, Liu, Dongxin, additional, Zheng, Huiwen, additional, Ma, Aijing, additional, Zhao, Bing, additional, Ou, Xichao, additional, Xia, Hui, additional, Wang, Shengfen, additional, and Zhao, Yanlin, additional

Published
2022
Full Text
View/download PDF

22. Strong Increase in Moxifloxacin Resistance Rate among Multidrug-Resistant Mycobacterium tuberculosis Isolates in China, 2007 to 2013

Author

Xia, Hui, Zheng, Yang, Liu, Dongxin, Wang, Shengfen, He, WenCong, Zhao, Bing, Song, Yuanyuan, Ou, Xichao, Zhou, Yang, van den Hof, Susan, Cobelens, Frank, and Zhao, Yanlin

Subjects
resistance, moxifloxacin, multidrug-resistant tuberculosis
Abstract

We designed this study to determine the trend of moxifloxacin resistance among multidrug-resistant tuberculosis (MDR-TB) patients from 2007 to 2013 in China to inform the composition of multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment regimens. We assessed moxifloxacin resistance among MDR-TB isolates collected in national drug resistance surveys in 2007 and 2013 that included 3,634 smear-positive and 7,206 culture-positive pulmonary tuberculosis patients, respectively. Moxifloxacin susceptibility was examined by a Mycobacterium growth indicator tube (MGIT) 960 for the 2007 isolates, and by the minimum inhibitory concentration (MIC) method for the 2013 isolates, at both breakpoints 0.5 and 2.0 μg/mL. Risk factors were explored through multivariable log-binominal regression analysis. Mutations in gyrA and gyrB for part of the isolates were also studied through sequencing. Of 401 MDR strains isolated in 2007, moxifiloxacin resistance could be determined for 319 (79.6%): 41 (12.9%) and 10 (3.1%) were resistant at 0.5 and 2.0 μg/mL, respectively. Of 365 MDR strains isolated in 2013, 338 (92.6%) could be analyzed: 140 (41.4%) and 79 (23.4%) were resistant at 0.5 and 2.0 μg/mL. For patients in 2007, no characteristics were significantly associated with moxifloxacin resistance. For patients in 2013, patients aged ≥60 years (adjusted prevalence ratio [aPR], 1.46; 95% confidence interval [CI], 1.10 to 1.93) were more likely to have resistance at 0.5 μg/mL, whereas those residing in eastern China compared to those in central China had an increased risk of resistance at both 0.5 (aPR, 1.85; 95% CI, 1.38 to 2.48) and 2.0 μg/mL (aPR, 2.14; 95% CI, 1.35 to 3.40). Sequencing results were obtained for 245 and 266 MDR-TB isolates in 2007 and 2013, respectively. In total, 34 of 38 (89.5%) and 89 of 104 (85.6%) of 2007 and 2013 moxifloxacin-resistant (0.5 μg/mL) MDR-TB strains had mutations in the gyrA and gyrB gene, respectively. Asp94Gly was the most common mutation among 2007 (11 of 38, 28.9%) and 2013 isolates (24 of 104, 23.1%) and conferred high-level moxifloxacin resistance. Moxifloxacin resistance among MDR-TB patients in China increased from modest to high from 2007 to 2013. Moxifloxacin should be used carefully as a potentially effective drug for composing MDR/RR-TB regimens especially for elderly patients in China. Individual susceptibility testing especially rapid molecular-based assays should be conducted to confirm the susceptibility to moxifloxacin. IMPORTANCE China is one of the high-burden countries for multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB). Moxifloxacin is one of the critical antituberculosis drugs for MDR/RR-TB treatment. Susceptibility to moxifloxacin is therefore very important to compose effective regimens and to provide protection against development of resistance of companion drugs such as bedaquiline and linezolid. There are, however, no nationally representative data on moxifloxacin resistance among MDR/RR-TB cases in China. Therefore, we assessed the resistance prevalence for moxifloxacin among MDR-TB strains isolated in national drug resistance surveys in 2007 and 2013 that covered 72 sites around the country. We demonstrate that the prevalence of moxifloxacin resistance in MDR-TB isolates increased from modest to high, which should prompt the national tuberculosis program to use moxifloxacin cautiously in second-line regimens to treat MDR/RR-TB unless susceptibility can be laboratory-confirmed.

Published
2021

23. Strong Increase in Moxifloxacin Resistance Rate among Multidrug-Resistant Mycobacterium tuberculosis Isolates in China, 2007 to 2013

Author

Xia, Hui, primary, Zheng, Yang, additional, Liu, Dongxin, additional, Wang, Shengfen, additional, He, WenCong, additional, Zhao, Bing, additional, Song, Yuanyuan, additional, Ou, Xichao, additional, Zhou, Yang, additional, van den Hof, Susan, additional, Cobelens, Frank, additional, and Zhao, YanLin, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results